Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease VirusComplete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
/in Breast Cancer, Checkpoint-Inhibitors, Hyperthermia, International PublicationsPhase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsCombining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
/in Checkpoint-Inhibitors, International PublicationsLysis-independent potentiation of immune checkpoint blockade by oncolytic virus
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusImmunotherapy of Hepatocellular Carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, Hepatocellular Carcinoma, International Publications, Newcastle Disease VirusPD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusDendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International PublicationsAnti-cancer vaccine therapy for hematologic malignancies: An evolving era
/in Acute Leukemia, Checkpoint-Inhibitors, Chronic Leukemia, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de